Solventum vs Teladoc Health
Solventum is the larger business, with $8.32bn of revenue in fiscal 2025 against $2.53bn for Teladoc Health (3.3 times as much). Solventum grew faster (0.9% against -1.5%). Solventum kept more of each dollar of sales as profit: a net margin of 18.7% against -7.9%.
| Latest fiscal year | SolventumSOLV, 2025 | Teladoc HealthTDOC, 2025 |
|---|---|---|
| Revenue | $8.32bn | $2.53bn |
| Revenue growth | 0.9% | -1.5% |
| Net income | $1.56bn | −$200m |
| Operating margin | 26.2% | — |
| Net margin | 18.7% | -7.9% |
| Return on equity | 38.9% | -13.9% |
| Free cash flow | −$10.0m | $285m |
| Cash | $878m | $781m |
| Total debt | $5.08bn | $995m |
| Debt to equity | 100.7% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 22,000 | 5,600 |
| Market value | $14.40bn | $1.62bn |
| Price vs our value range | — | Below our value range |
| Moat score | — | 36 (Weak) |
| Insider trades, 12 months | 1 buys, 0 sales | 1 buys, 37 sales |